+Compare
PTPI
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
2.8M

PTPI Petros Pharmaceuticals Forecast, Technical & Fundamental Analysis

a clinical stage biopharmaceutical and diagnostics company

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for PTPI with price predictions
07:00 PM EST Nov 30, 2023

PTPI in -0.92% downward trend, sliding for three consecutive days on November 28, 2023

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where PTPI declined for three days, in of 359 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for PTPI moved out of overbought territory on December 01, 2023. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

PTPI broke above its upper Bollinger Band on November 29, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for PTPI entered a downward trend on November 20, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 62 cases where PTPI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on November 28, 2023. You may want to consider a long position or call options on PTPI as a result. In of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for PTPI just turned positive on November 15, 2023. Looking at past instances where PTPI's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .

PTPI moved above its 50-day moving average on November 30, 2023 date and that indicates a change from a downward trend to an upward trend.

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where PTPI advanced for three days, in of 213 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.412) is normal, around the industry mean (47.989). P/E Ratio (0.000) is within average values for comparable stocks, (60.542). PTPI's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.883). PTPI has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.027). P/S Ratio (0.397) is also within normal values, averaging (65.502).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. PTPI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PTPI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Intra-Cellular Therapies (NASDAQ:ITCI), Bausch Health Companies (NYSE:BHC), Tilray Brands (NASDAQ:TLRY), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 2.76B. The market cap for tickers in the group ranges from 246 to 82.08B. ZTS holds the highest valuation in this group at 82.08B. The lowest valued company is PEMTF at 246.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was 3%. For the same Industry, the average monthly price growth was 39%, and the average quarterly price growth was -6%. RDHL experienced the highest price growth at 426%, while CNTRF experienced the biggest fall at -57%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 204%. For the same stocks of the Industry, the average monthly volume growth was 17% and the average quarterly volume growth was 37%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 55
P/E Growth Rating: 68
Price Growth Rating: 61
SMR Rating: 84
Profit Risk Rating: 91
Seasonality Score: 24 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published General Information

General Information

a clinical stage biopharmaceutical and diagnostics company

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Medical Specialties
Address
1185 Avenue of the Americas
Phone
+1 973 242-0005
Employees
24
Web
https://www.petrospharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VTSI7.820.46
+6.25%
VirTra
AGFY1.480.07
+4.96%
Agrify Corp
SPFI27.281.28
+4.92%
South Plains Financial
ORI29.390.08
+0.27%
Old Republic International Corp
EVEX6.98-0.08
-1.13%
Eve Holding

PTPI and

Correlation & Price change

A.I.dvisor tells us that PTPI and ESPR have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PTPI and ESPR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PTPI
1D Price
Change %
PTPI100%
-8.13%
ESPR - PTPI
29%
Poorly correlated
+8.27%
RDHL - PTPI
26%
Poorly correlated
-17.00%
SNDL - PTPI
25%
Poorly correlated
+4.90%
ACET - PTPI
23%
Poorly correlated
+4.24%
LFCR - PTPI
23%
Poorly correlated
+2.65%
More

Groups containing PTPI

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PTPI
1D Price
Change %
PTPI100%
-8.13%
biopharmaceuticals
(undefined stocks)
11%
Poorly correlated
+2.15%
diagnostics
(undefined stocks)
10%
Poorly correlated
+1.78%
medical research
(undefined stocks)
4%
Poorly correlated
+2.76%
medical service
(undefined stocks)
3%
Poorly correlated
+2.66%
Pharmaceuticals
(undefined stocks)
1%
Poorly correlated
+1.51%
More